Sanofi (SNY) Given a $48.00 Price Target at Cowen

Sanofi (NYSE:SNY) has been given a $48.00 price objective by research analysts at Cowen in a report released on Monday. The brokerage presently has a “hold” rating on the stock. Cowen’s price target would suggest a potential upside of 10.37% from the stock’s previous close.

Other equities analysts have also recently issued reports about the company. Argus reissued a “buy” rating and issued a $55.00 price target on shares of Sanofi in a report on Friday, September 1st. Barclays raised Sanofi from an “underweight” rating to an “equal weight” rating in a report on Wednesday, November 15th. raised Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. Finally, Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a report on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company’s stock. Sanofi currently has an average rating of “Hold” and an average price target of $51.50.

Sanofi (NYSE:SNY) traded up $0.32 on Monday, reaching $43.49. The company’s stock had a trading volume of 1,587,418 shares, compared to its average volume of 1,498,658. Sanofi has a one year low of $38.67 and a one year high of $50.65. The stock has a market capitalization of $108,853.50, a P/E ratio of 13.62, a price-to-earnings-growth ratio of 2.56 and a beta of 0.86. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sei Investments Co. increased its stake in Sanofi by 837.0% in the fourth quarter. Sei Investments Co. now owns 412,386 shares of the company’s stock valued at $17,589,000 after purchasing an additional 368,375 shares during the last quarter. Tocqueville Asset Management L.P. increased its stake in Sanofi by 14.3% in the second quarter. Tocqueville Asset Management L.P. now owns 255,713 shares of the company’s stock valued at $10,702,000 after purchasing an additional 31,980 shares during the last quarter. Prentiss Smith & Co. Inc. increased its stake in Sanofi by 0.6% in the fourth quarter. Prentiss Smith & Co. Inc. now owns 154,488 shares of the company’s stock valued at $6,589,000 after purchasing an additional 859 shares during the last quarter. Bank of Montreal Can increased its stake in Sanofi by 0.7% in the fourth quarter. Bank of Montreal Can now owns 389,519 shares of the company’s stock valued at $16,614,000 after purchasing an additional 2,560 shares during the last quarter. Finally, World Asset Management Inc increased its stake in Sanofi by 2.3% in the fourth quarter. World Asset Management Inc now owns 103,759 shares of the company’s stock valued at $4,425,000 after purchasing an additional 2,365 shares during the last quarter. 9.09% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Market News and is the property of of American Market News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/18/sanofi-sny-given-a-48-00-price-target-at-cowen.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.